EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?

Mesud Mustafic, Rebecka Jandér, David Marlevi, Anette Rickenlund, Andreas Rück, Nawzad Saleh, Sam Abdi, Maria J Eriksson, Anna Damlin

Cardiovascular Intervention and Therapeutics · 2024-10 · 39 (4) · 479-489

DOI: 10.1007/s12928-024-01014-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, online erschienen am 28.05.2024. Verfasst von Mesud Mustafic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Mitral Valve, Ethanol, Ablation Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Heart-Lung foundation, European Union, Hjärt-Lungfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective cohort study aimed to assess whether basal septal wall thickness (BSWT), anterior (AML) and posterior (PML) mitral leaflet length, or sex were associated with remaining left ventricular outflow tract obstruction (LVOTO) in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing alcohol septal ablation (ASA). One hundred fifty-four patients who underwent ASA at the Karolinska University Hospital in Stockholm, Sweden, between 2009 and 2021, were included retrospectively. Anatomical and hemodynamic parameters were collected from invasive catheterization before and during ASA, and from echocardiography (ECHO) examinations before, during, and at 1-year follow-up after ASA. Linear and logistic regression models were used to assess the association between sex, BSWT, AML, PML, and outcome, which was defined as the remaining LVOTO (≥ 30 mmHg) after ASA. The median follow-up was 364 days (interquartile range 334–385 days). BSWT ≥ 23 mm ( n = 13, 12%) was associated with remaining LVOTO at follow-up ( p = 0.004). Elongated mitral valve leaflet length (either AML or PML) was present in 125 (90%) patients. Elongated AML (> 24 mm) was present in 67 (44%) patients, although AML length was not associated with remaining LVOTO at follow-up. Elongated PML (> 14 mm) was present in 114 (74%) patients and was not associated with remaining LVOTO at follow-up. No significant sex differences were observed regarding the remaining LVOTO. ECHO measurement of BSWT can be effectively used to select patients for successful ASA and identify those patients with a risk of incomplete resolution of LVOTO after ASA. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicMitral ValveEthanolAblation TechniquesVentricular Outflow ObstructionHeart SeptumHumansMaleFemaleRetrospective StudiesMiddle AgedSex FactorsAgedEchocardiographyTreatment Outcome

Stichwörter der Autor:innen

Alcohol septal ablationAnterior mitral valve leafletBasal septal wall thicknessEchocardiographyHypertrophic obstructive cardiomyopathySex differences

Substanzen

Ethanol

Autor:innen und Institutionen

  • Division of Clinical Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Clinical Physiology, Karolinska University Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Cardiology, Karolinska University Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Unit of Cardiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Internal Medicine, Karolinska University Hospital, Stockholm, Sweden.

Förderung

  • Swedish Heart-Lung foundation
  • European Union
  • Hjärt-Lungfonden
  • Karolinska Institute

Zitieren

APA

Mustafic, M., Jandér, R., Marlevi, D., Rickenlund, A., Rück, A., Saleh, N., Abdi, S., Eriksson, M. J., & Damlin, A. (2024). Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?. Cardiovascular Intervention and Therapeutics, 39(4), 479-489. https://doi.org/10.1007/s12928-024-01014-4

Vancouver

Mustafic M, Jandér R, Marlevi D, Rickenlund A, Rück A, Saleh N, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?. Cardiovascular Intervention and Therapeutics. 2024;39(4):479-489. doi:10.1007/s12928-024-01014-4

BibTeX
@article{Mustafic2024,
  author = {Mustafic, Mesud and Jandér, Rebecka and Marlevi, David and Rickenlund, Anette and Rück, Andreas and Saleh, Nawzad and Abdi, Sam and Eriksson, Maria J and Damlin, Anna},
  title = {Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?},
  journal = {Cardiovascular Intervention and Therapeutics},
  year = {2024},
  volume = {39},
  number = {4},
  pages = {479--489},
  doi = {10.1007/s12928-024-01014-4}
}
Kostenlos starten →